“Summer is the perfect time to embrace crisp, sessionable brews with bright flavors,” said Prinz Pinakatt, Chief Growth ...

About DIOSynVax DIOSynVax is a clinical-stage biotechnology company focused on developing universal vaccines using cutting-edge artificial intelligence technologies. The company's mission is to ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the entry ...

ARLINGTON, Va., June 05, 2025 (GLOBE NEWSWIRE) -- Tria Federal has promoted Atchut Kanthamani to the new position of President. In this role, he will lead Tria's business growth and technology ...

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that management will ...

SARASOTA, FL, June 05, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug ...

Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY ® Endovascular Robotic System, announced that it has been selected for inclusion in the preliminary list of additions to the ...

Move allows for expansion of production capabilities in Gardner, MA to meet increased backlog ...

Gastroenterology, the premier journal in gastrointestinal science, features data supporting inFoods IBS as an effective personalized, non-drug approach for managing IBS. Study results suggest inFoods ...

“A perfect operation can still be compromised if travel plans are prioritized over medical advice or if symptoms such as ...

Ocugen is currently advancing OCU400 through Phase 3 clinical development with a target Biologics License Application filing of mid-2026.